{"transactions":[{"id":695830,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-05T22:36:52.000Z","date":"2026-08-03","kind":"sale","planned":false,"acquired":false,"shares":2447,"price":26.37,"value":64527.39,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":56892,"source":{"system":"sec-edgar","filing":"0001789317-26-000007","document":"form4-08052026_100847.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000178931726000007/form4-08052026_100847.xml","form_type":"4"}},{"id":761992,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-27T23:06:45.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":false,"shares":15535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vested on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":164465,"derivative":{"exercise_price":5.06,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":15535},"source":{"system":"sec-edgar","filing":"0001789317-26-000005","document":"form4-05272026_110540.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000178931726000005/form4-05272026_110540.xml","form_type":"4"}},{"id":761991,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-27T23:06:45.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":false,"shares":11317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":159805,"derivative":{"exercise_price":8.84,"expiration_date":"2032-08-29","underlying":"Common Stock","underlying_shares":11317},"source":{"system":"sec-edgar","filing":"0001789317-26-000005","document":"form4-05272026_110540.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000178931726000005/form4-05272026_110540.xml","form_type":"4"}},{"id":761990,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-27T23:06:45.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":true,"shares":15535,"price":5.06,"value":78607.1,"ownership":{"direct":true},"balance_after":59339,"source":{"system":"sec-edgar","filing":"0001789317-26-000005","document":"form4-05272026_110540.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000178931726000005/form4-05272026_110540.xml","form_type":"4"}},{"id":761989,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-27T23:06:45.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":true,"shares":11317,"price":8.84,"value":100042.28,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,037 shares acquired on November 20, 2025 and 3,000 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":43804,"source":{"system":"sec-edgar","filing":"0001789317-26-000005","document":"form4-05272026_110540.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000178931726000005/form4-05272026_110540.xml","form_type":"4"}},{"id":929066,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-29T00:17:47.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":221450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."}],"balance_after":221450,"derivative":{"exercise_price":26.31,"expiration_date":"2036-01-25","underlying":"Common Stock","underlying_shares":221450},"source":{"system":"sec-edgar","filing":"0001789317-26-000003","document":"form4-01292026_120144.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000178931726000003/form4-01292026_120144.xml","form_type":"4"}},{"id":1078443,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-01T01:05:10.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":101850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vest on July 29, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."}],"balance_after":101850,"derivative":{"exercise_price":3.95,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":101850},"source":{"system":"sec-edgar","filing":"0001415889-25-020803","document":"form4-07312025_090706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925020803/form4-07312025_090706.xml","form_type":"4"}},{"id":1078442,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-01T01:05:10.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":25450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant. 25% of the shares underlying this RSU vest on August 1, 2026, and the remaining shares vest in equal quarterly installments thereafter over the following 12 quarters, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares acquired on May 20, 2025 under the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":28450,"source":{"system":"sec-edgar","filing":"0001415889-25-020803","document":"form4-07312025_090706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925020803/form4-07312025_090706.xml","form_type":"4"}},{"id":1256003,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T23:30:10.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":180000,"derivative":{"exercise_price":5.06,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001415889-25-004938","document":"form4-02202025_060206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925004938/form4-02202025_060206.xml","form_type":"4"}},{"id":1465925,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":64171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":64171,"derivative":{"exercise_price":13.33,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":64171},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465924,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":64171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.33,"expiration_date":"2034-06-05","underlying":"Class A Common Stock","underlying_shares":64171},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465923,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":70802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":70802,"derivative":{"exercise_price":10.2,"expiration_date":"2034-05-05","underlying":"Common Stock","underlying_shares":70802},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465922,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.2,"expiration_date":"2034-05-05","underlying":"Class A Common Stock","underlying_shares":70802},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465921,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":54545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":54545,"derivative":{"exercise_price":8.84,"expiration_date":"2034-03-28","underlying":"Common Stock","underlying_shares":54545},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465920,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":54545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2034-03-28","underlying":"Class A Common Stock","underlying_shares":54545},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465919,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":18652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":18652,"derivative":{"exercise_price":8.84,"expiration_date":"2033-10-08","underlying":"Common Stock","underlying_shares":18652},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465918,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2033-10-08","underlying":"Class A Common Stock","underlying_shares":18652},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465917,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":12834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":12834,"derivative":{"exercise_price":8.84,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":12834},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465916,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2033-06-22","underlying":"Class A Common Stock","underlying_shares":12834},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465915,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":171122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":171122,"derivative":{"exercise_price":8.84,"expiration_date":"2032-08-29","underlying":"Common Stock","underlying_shares":171122},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465914,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":171122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2032-08-29","underlying":"Class A Common Stock","underlying_shares":171122},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465913,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":85561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33% of the shares underlying this option vested on August 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":85561,"derivative":{"exercise_price":8.84,"expiration_date":"2032-08-29","underlying":"Common Stock","underlying_shares":85561},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465912,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33% of the shares underlying this option vested on August 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2032-08-29","underlying":"Class A Common Stock","underlying_shares":85561},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465911,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":5347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":5347,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":5347},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465910,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Class A Common Stock","underlying_shares":5347},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1465909,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:37:25.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":5347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":5347,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Class A Common Stock","underlying_shares":5347},"source":{"system":"sec-edgar","filing":"0001415889-24-018592","document":"form4-07012024_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018592/form4-07012024_080720.xml","form_type":"4"}},{"id":1508531,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:12:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000099","document":"wk-form4_1716250361.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1626199/000162619924000099/wk-form4_1716250361.xml","form_type":"4"}},{"id":1508530,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:12:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000099","document":"wk-form4_1716250361.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1626199/000162619924000099/wk-form4_1716250361.xml","form_type":"4"}},{"id":1508529,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-20T20:12:51.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option shall become vested and exercisable on 08/18/2022 and 1/36th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2032-07-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001626199-24-000099","document":"wk-form4_1716250361.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626199/000162619924000099/wk-form4_1716250361.xml","form_type":"4"}},{"id":1686923,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-04T19:05:44.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":17500,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000012","document":"wk-form4_1704413131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626199/000162619924000012/wk-form4_1704413131.xml","form_type":"4"}},{"id":2061681,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-01-05T18:59:14.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":10000,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-23-000019","document":"wf-form4_167296313903992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626199/000162619923000019/wf-form4_167296313903992.xml","form_type":"4"}},{"id":2205062,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-07-19T16:42:33.000Z","date":"2022-07-18","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall become vested and exercisable on 08/18/2022 and 1/36th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":20000,"derivative":{"exercise_price":8.71,"expiration_date":"2032-07-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001789317-22-000004","document":"wf-form4_165826334018650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626199/000178931722000004/wf-form4_165826334018650.xml","form_type":"4"}},{"id":2411829,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-04T23:38:05.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month).  \"Vesting Commencement Date\" shall mean February 3, 2022."}],"balance_after":145000,"derivative":{"exercise_price":12.21,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000899243-22-004895","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851194/000089924322004895/doc4.xml","form_type":"4"}},{"id":2788630,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:16:17.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":165000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."}],"balance_after":0,"derivative":{"exercise_price":2.84,"expiration_date":"2028-05-10","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0000899243-21-011499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011499/doc4.xml","form_type":"4"}},{"id":2788629,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:16:17.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":64000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."}],"balance_after":0,"derivative":{"exercise_price":15.84,"expiration_date":"2029-08-25","underlying":"Common Stock","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0000899243-21-011499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011499/doc4.xml","form_type":"4"}},{"id":2788628,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:16:17.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":71842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047."}],"balance_after":0,"derivative":{"exercise_price":41.1,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":71842},"source":{"system":"sec-edgar","filing":"0000899243-21-011499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011499/doc4.xml","form_type":"4"}},{"id":2788627,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-15T09:16:17.000Z","date":"2021-03-13","kind":"disposition_to_issuer","acquired":false,"shares":202661,"price":53,"value":10741033.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the \"Merger Agreement\"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. (\"Purchaser\"), and for certain purposes, Horizon Therapeutics plc (\"Ultimate Parent\"), including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-011499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011499/doc4.xml","form_type":"4"}},{"id":3226213,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":26267,"kind":"person","name":"Drappa Jorn","position":1,"cik":"0001789317","reported_name":"Drappa Jorn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T16:44:46.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":71842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant vests as to 25% of the shares on March 2, 2021 with the remainder vesting in equal installments every three months thereafter and ending on March 2, 2024."}],"balance_after":71842,"derivative":{"exercise_price":41.1,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":71842},"source":{"system":"sec-edgar","filing":"0001209191-20-016146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000120919120016146/doc4.xml","form_type":"4"}}]}